https://scholars.lib.ntu.edu.tw/handle/123456789/578076
標題: | Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study | 作者: | Liou B.-H. HSIN-YUN SUN Yang C.-J. Syue L.-S. Lee Y.-L. Tang H.-J. Tsai H.-C. Lin C.-Y. Chen T.-C. Lee C.-Y. Huang S.-H. Liu C.-W. Lu P.-L. Lin S.-P. Wang N.-C. ARISTINE CHENG Ko W.-C. Cheng S.-H. CHIEN-CHING HUNG the Taiwan HIV Study Group |
公開日期: | 2021 | 出版社: | Adis | 卷: | 10 | 期: | 2 | 起(迄)頁: | 827-838 | 來源出版物: | Infectious Diseases and Therapy | 摘要: | Introduction: While coformulated ledipasvir (90?mg)/sofosbuvir (400?mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods: From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12?weeks off-therapy (SVR12). Results: Of the 114 patients (mean age, 38.6?years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR)?>?30?ml/min/1.73?m2 and were receiving antiretroviral therapy with 98.2% having CD4 counts???200 cells/mm3 and 93.9% plasma HIV RNA load?<?50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, ??8.33?ml/min/1.73?m2), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion: Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2. ? 2021, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103069272&doi=10.1007%2fs40121-021-00424-8&partnerID=40&md5=736e4bd066b5affbd28a7e051a966945 https://scholars.lib.ntu.edu.tw/handle/123456789/578076 |
ISSN: | 2193-8229 | DOI: | 10.1007/s40121-021-00424-8 | SDG/關鍵字: | alanine aminotransferase; amiodarone; aspartate aminotransferase; entecavir; integrase inhibitor; lamivudine; ledipasvir; phenytoin; proteinase inhibitor; sofosbuvir; acute hepatitis C; adult; antiretroviral therapy; Article; cell cycle arrest; chronic hepatitis B; chronic kidney failure; coinfection; comparative effectiveness; data analysis software; echography; estimated glomerular filtration rate; female; genotype; hemodialysis; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; Human immunodeficiency virus; liver cirrhosis; major clinical study; male; multicenter study; prevalence; retrospective study; viremia; virus load; virus replication |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。